Multivariate analysis for transplantation outcome
| Variables . | P . | HR (95% CI) . |
|---|---|---|
| Overall survival | ||
| Early disease | <.001 | 0.33 (0.22-0.50) |
| CT60 AG/GG | .001 | 3.80 (1.75-8.22) |
| +49 AG/GG | .564 | 0.88 (0.56-1.37) |
| Donor CMV+ | .468 | 1.21 (0.72-2.04) |
| Sensitized donor | .538 | 1.18 (0.70-1.98) |
| Stem cell source | .124 | 1.40 (0.91-2.14) |
| Diagnosis | .741 | 1.08 (0.69-1.68) |
| Age younger than 30 y | .113 | 1.42 (0.92-2.18) |
| aGVHD II-IV | ||
| Stem cell source | .041 | 1.49 (1.01-2.20) |
| CT60 AG/GG | .033 | 0.62 (0.40-0.96) |
| +49 AG/GG | .587 | 0.87 (0.54-1.41) |
| Donor CMV+ | .276 | 1.28 (0.81-2.03) |
| Sex mismatch | .543 | 1.15 (0.73-1.79) |
| 1722 CC/CT | .055 | 1.63 (0.99-2.67) |
| Relapse | ||
| Age younger than 30 y | .019 | 0.61 (0.41-0.92) |
| Early disease | <.001 | 0.37 (0.25-0.56) |
| Patient CMV+ | .008 | 2.08 (1.20-3.57) |
| CT60 AG/GG | .049 | 1.71 (1.00-2.93) |
| Donor CMV+ | .158 | 1.48 (0.86-2.53) |
| Conditioning regimen | .958 | 0.99 (0.64-1.52) |
| Diagnosis | .643 | 1.10 (0.73-1.68) |
| Variables . | P . | HR (95% CI) . |
|---|---|---|
| Overall survival | ||
| Early disease | <.001 | 0.33 (0.22-0.50) |
| CT60 AG/GG | .001 | 3.80 (1.75-8.22) |
| +49 AG/GG | .564 | 0.88 (0.56-1.37) |
| Donor CMV+ | .468 | 1.21 (0.72-2.04) |
| Sensitized donor | .538 | 1.18 (0.70-1.98) |
| Stem cell source | .124 | 1.40 (0.91-2.14) |
| Diagnosis | .741 | 1.08 (0.69-1.68) |
| Age younger than 30 y | .113 | 1.42 (0.92-2.18) |
| aGVHD II-IV | ||
| Stem cell source | .041 | 1.49 (1.01-2.20) |
| CT60 AG/GG | .033 | 0.62 (0.40-0.96) |
| +49 AG/GG | .587 | 0.87 (0.54-1.41) |
| Donor CMV+ | .276 | 1.28 (0.81-2.03) |
| Sex mismatch | .543 | 1.15 (0.73-1.79) |
| 1722 CC/CT | .055 | 1.63 (0.99-2.67) |
| Relapse | ||
| Age younger than 30 y | .019 | 0.61 (0.41-0.92) |
| Early disease | <.001 | 0.37 (0.25-0.56) |
| Patient CMV+ | .008 | 2.08 (1.20-3.57) |
| CT60 AG/GG | .049 | 1.71 (1.00-2.93) |
| Donor CMV+ | .158 | 1.48 (0.86-2.53) |
| Conditioning regimen | .958 | 0.99 (0.64-1.52) |
| Diagnosis | .643 | 1.10 (0.73-1.68) |
Patient/donor CMV+ indicates positive IgG cytomegalovirus serology. Stem cell source was stratified as peripheral blood versus bone marrow. Diagnosis was stratified in acute leukemia/MDS versus other. Conditioning regimen was stratified in total body irradiation containing regimens versus chemotherapy alone.